XML 75 R36.htm IDEA: XBRL DOCUMENT v2.4.0.6
INTANGIBLE ASSETS (Tables)
12 Months Ended
Dec. 31, 2012
Schedule Of Intangible Assets

Intangible assets consisted of the following:

 

     December 31,  
     2012     2011  

Intangible assets:

    

Finite-lived intangible assets

   $ 118,242      $ 118,242   

Indefinite-lived intangible assets

     63,689        70,396   
  

 

 

   

 

 

 

Gross intangible assets:

     181,931        188,638   

Less: Accumulated amortization

     (18,951     (8,361
  

 

 

   

 

 

 

Net carrying value

   $ 162,980      $ 180,277   
  

 

 

   

 

 

 
Schedule Of Amortization Of Finite-Lived Intangible Assets

The following table summarizes the annual amortization of the finite-lived intangible assets through 2023:

 

     Net Balance at
December  31, 2012
     Estimated
Useful  Life
     Remaining
Life
     Annual
Amortization
 

Naglazyme intellectual property

   $ 73,688         12 years         10.9 years       $ 6,750   

EU marketing rights for Firdapse

     23,364         10 years         7.3 years         3,223   

License payment for Kuvan FDA Approval

     648         7 years         1.9 years         332   

License payment for Kuvan EMEA Approval

     1,591         10 years         5.9 years         269   
  

 

 

          

 

 

 

Total

   $ 99,291             $ 10,574   
  

 

 

          

 

 

 
Schedule Of Indefinite-Lived Intangible Assets

Indefinite-lived intangible assets consisted of the following:

 

     December 31,  
     2012      2011  

In-Process Research and Development:

     

U.S. marketing rights for Firdapse

   $ 0       $ 6,707   

BMN-673 acquired through LEAD

     36,089         36,089   

BMN-701 acquired through ZyStor

     25,010         25,010   

Other acquired pre-clinical compounds

     2,590         2,590   
  

 

 

    

 

 

 

Net carrying value

   $ 63,689       $ 70,396